Five years as EMA Liaison at US FDA
|
|
- Buddy Carr
- 6 years ago
- Views:
Transcription
1 Five years as EMA Liaison at US FDA TOPRA Annual Human Medicines Symposium 2 4 October Victoria Park Plaza Hotel, London Presented by Dr Sabine Haubenreisser on 2 October 2017 European Medicines Agency, International Affairs An agency of the European Union
2 Disclaimer These PowerPoint slides are copyright of the European Medicines Agency. Reproduction is permitted provided the source is acknowledged. 1
3 EU-EMA/FDA cooperation Long history of informal cooperation with FDA (EC and individual member states) before there was an EMA. Informal cooperation between EMA and FDA after creation of EMA. Cooperation formalised: Confidentiality Commitment 2003, updated 2010 and extended indefinitely Implementation Plan 2004, updated
4 EMA/FDA confidentiality arrangement Legal basis: protection of non-public information provided in confidence Allows for sharing of non-public, pre-decisional information and draft legislation and guidance Foresees exchanges of staff (secondments, training), experts attendance and participation in scientific meetings Envisages information exchange in agreed areas, and types of exchange, eg, inspections, clusters Allows flexibility in dealing with ad hoc matters and broadening of fields of interest Provides for monitoring through yearly EU/FDA bilateral meeting A framework for regulatory cooperation, including exchange of information on advance drafts of legislation and regulatory guidance documents, as well as nonpublic information related to ensuring the quality, safety and efficacy of medicinal products for human and veterinary use, including orphan medicinal products, authorised or under review both in the USA and the EU 3
5 Practical experience of the confidentiality arrangements some thoughts Operate on basis of shared interests / mutual agreement on specified matters Legal constraints on information exchange (e.g. trade secret ) Arrangements are open to future development and broadening, without change to the implementation plan Key to working: cooperation, achieved through timely exchange of information and understanding, developing trust, building alliances 4
6 Role of the EMA liaison Facilitation of regulatory and scientific dialogue between EMA and FDA Identification of new and extended areas of cooperation Liaison with other relevant bodies and organisations Support awareness and understanding within FDA and amongst stakeholders of the regulatory cooperation To support and develop the regulatory cooperation between the European Medicines Agency (EMA) and US Food and Drug Administration (FDA) 5
7 Some key responsibilities of the EMA Liaison Act as source of knowledge for FDA on EU and EMA regulatory matters Facilitate information exchange, attend cluster meetings, handle requests, overcome differences of understanding or position Propose, initiate and frame programme of fellowships (3-8 per year) of EMA staff at FDA, obtain buy-in from FDA hosts Ensure early heads up on regulatory decisions, including background information and draft public communications Prepare for and follow-up EMA-EU/ FDA bilateral meetings Identify and propose new areas for regulatory cooperation and ways to develop and extend existing areas Increase awareness of interaction with EMA, through presentations within FDA and participation at conferences, universities and educational programmes 6
8 Overview of current platforms for exchange: Clusters Increased to 14 clusters Advanced-therapy medicinal products (2008) Biosimilars (2011) Blood products (2010) Non-clinical oncology (2011) Oncology-haematology medicinal products (2004) Orphan medicinal products (2008) Paediatric medicinal products (2007) Patient engagement (2016) Pharmacogenomics (2005) Pharmacometrics / Modelling and simulation (2016) Pharmacovigilance (2013) Rare diseases (2016) Vaccines (2005) Veterinary medicinal products (2005) 7
9 Overview of current platforms for exchange: other platforms Formal platforms / interactions: International API Inspection Programme Teleconference (2012) EMA-FDA GCP initiative (2009) Bioequivalence (2014) Scientific Advice/Parallel Scientific Advice Interactions for medicines of human and veterinary use (2005) Shortages due to GMP non-compliance and quality defects (2013) Veterinary quarterly bilateral Informal bilateral teleconferences: Anti-infectives Cardiovascular Neurology/Psychiatry Pulmonary/Allergy/Rheumatology Veterinary novel therapies (2016) Veterinary pharmacovigilance (2016) 8
10 Advances in cooperation (1) Orphan medicines Single application form and annual report Paediatric medicines Increasing number of common commentaries Parallel EMA-FDA scientific advice Widened opportunities for parallel scientific advice and opened possibility of consultative advice Parallel submissions for qualification of Biomarkers or Clinical Outcome Measures Joint template agreed and published In all cases goals are the same: Support global development plans Scientific and public health convergence Reduce administrative burden 9
11 Advances in cooperation (2) Prime / Breakthrough Therapy Quarterly meetings comparing (Oncology pilot, engaging experts as early as possible for dual designated applications) New clusters: Patient engagement Rare diseases Pharmacometrics Increased cooperation in Biosimilars FDA gives advance notice on planned communications including Drug Safety Communications Awareness of ongoing evaluations, opportunity for discussion, exchange of views Advance notice of important regulatory action Understanding in case of different outcomes 10 10
12 International exchange on shortages Reinstated quarterly teleconference on shortages due to manufacturing quality issues Follows from EU initiative on minimising and preventing shortages relating to manufacturing and quality issues Raising awareness of existing shortages in different regions Update on programs within regions to prevent shortages Discuss reasons for shortages and ways to address them Rapid alert on identified shortages 11
13 GMP inspection initiatives API inspection programme Fosters greater international cooperation and information sharing to help to better distribute inspection capacity, allowing more sites to be monitored and reducing unnecessary duplication Involves WHO, EDQM, several EU Member States, FDA, TGA, Health Canada and PMDA EU/US Mutual Recognition Agreement Signed March 1st, 2017 Better use of inspection resources, avoiding duplication, increased inspection coverage Signature of Super CC (confidentiality arrangement allowing FDA to share full inspection reports, including trade secret information with EU regulators) August 3 rd,
14 GCP inspection initiatives GCP inspection initiative improved communications between agencies and strengthened trust in each other s efforts Covers new chemical entities and biologics and FDA-EMA inspections Conduct information exchanges on GCP-related information Conduct collaborative GCP inspections and share information on GCP inspections and interpretation of GCP Facilitates both agencies inspection coverage and decision-making GCP bioequivalence inspection initiative involves inspections within national programmes (UK, IT, DE, FR, NL, ES) Exchange of planned and conducted bioequivalence inspections Possibility of joint (system related) or observed inspections Aims to streamline inspection resources for bioequivalence studies 13
15 Fellowships Aim: advance scientific and regulatory understanding, usually a 2-week exchange 22 EMA fellowships at FDA in the last 4 years 5 more this year 2 currently in progress (MRA, Combination products) 14 This year: GMP inspections Extrapolation Regulatory procedures Combination products ISO standardisation Past years: GMP inspections (x2) Risk communication Raw data analysis (x2) Pharmacovigilance Qualification of clinical outcome measures ISO standardisation Patient engagement Veterinary medicines (x3) Legal aspects PhV inspections Accelerated access to medicines Rheumatology and gastroenterology Quality of medicines Transparency Communications Real world data and big data Orphan medicines Paediatric medicines
16 Progress supported by fellowships Creation of Patient Engagement cluster MRA on GMP inspections (3 related fellowships) Signing of Super CC confidentiality commitment allowing FDA to share trade secret information Increased heads up from FDA on advance notice of communications, alignment of messages / timing and lines to take Exchange on PRIME/ Breakthrough Therapy designation Oncology pilot Discussions on novel veterinary therapies and veterinary pharmacovigilance 15
17 Conclusion strong support for continuity Regulatory cooperation essential to meet challenges of globalisation on bilateral as well multilateral level EMA/FDA cooperation addresses relevant aspects of EU Medicines Agencies Network Strategy 2020 Assuring product supply chain and data integrity Convergence of global standards and contribution to international fora Ensuring best use of resources through promoting mutual reliance and work-sharing Supporting training and capacity building and promoting the EU regulatory model Sharing of expertise to meet challenges of globalisation 20 years experience of interactions and regular exchanges has led to better understanding and more readiness to engage on both sides Has established global pool of expertise and increased readiness to strive towards convergence 16
18 Conclusion looking ahead Need to join forces in: Addressing quality issues currently bottleneck for accelerated approvals Supporting innovation facilitating early access to medicines, development of ATMPs, making use of real world data Implementation of the MRA 17
19 Conclusion experience of last 5 years Liaison presence within hosting agency is invaluable feeding information in both directions, providing background, facilitating interactions, anticipating and acting on differences, finding common ground, overcoming hurdles Takes time to get to know colleagues, build trust, develop culture of cooperation, mutual reliance and strive systematically for convergence 18
20 Thank you for your attention Sabine Haubenreisser, MSc, PhD European Medicines Agency, International Affairs +44 (0) European Medicines Agency 30 Churchill Place Canary Wharf London E14 5EU United Kingdom Telephone +44 (0) Facsimile +44 (0) Send a question via our website Follow us EMA_News
EMA and international cooperation
EMA and international cooperation The EU medicines regulatory system and the European Medicines Agency: an introduction for international regulators and non-governmental organisations London, 18-19 September
More informationEMA / FDA efforts towards Regulatory Harmonisation - Transatlantic Trade and Investment Partnership (TTIP)
EMA / FDA efforts towards Regulatory Harmonisation - Transatlantic Trade and Investment Partnership (TTIP) European Health Forum - 3 rd October 2013 Falk Ehmann MD, PhD European Medicines Agency - London
More informationRecent update of the guidance for Parallel EMA/FDA scientific advice
Recent update of the guidance for Parallel EMA/FDA scientific advice Industry stakeholder platform on research and development support, 15.11.2017 Presented by Thorsten Vetter An agency of the European
More informationEU Update on Regulatory Developments
EU Update on Regulatory Developments Pascal Venneugues European Medicines Agency CASSS CMC Strategy Forum Europe Copenhagen, 4-6 May 2015 An agency of the European Union Overview International cooperation
More informationOverview of the Agency s role, activities and priorities for An agency of the European Union
Overview of the Agency s role, activities and priorities for 2015 An agency of the European Union The Agency's prioroties for 2015 In light of the above influences and other business-environment factors,
More informationAdvanced Therapies in Europe
Advanced Therapies in Europe 1 ATMPs in Europe (2009-2017) ~ 500 clinical trials using ATMPs in EU ~ 270 ATMP classifications 18 MAAs reviewed ~ 250 scientific advice requests 9 ATMPs approved 2 3 withdrawn
More informationWork plan for the GMP/GDP Inspectors Working Group for 2018
30 November 2017 EMA/INS/GMP/504401/2017 Inspections, Human Medicines Pharmacovigilance & Committees Division Work plan for the GMP/GDP Inspectors Working Group for 2018 Chairperson: Brendan Cuddy Adopted:
More informationIssues identified by stakeholders: follow-up from EMA s ATMP workshop
2 February 2017 EMA/48099/2017 Human Medicines Research and Development Support Division On 27 May 2016 EMA hosted a workshop 1 aimed to foster ATMP development and enable expanded patient access in the
More informationEU regulatory tools for expedited antibacterial development programmes
EU regulatory tools for expedited antibacterial development programmes Expediting antibacterial development: core lessons key tools for a rocky road, ECCMID 2018, Madrid Presented by Marco Cavaleri on
More informationWork plan for the GMP/GDP Inspectors Working Group for 2017
13 January 2017 EMA/INS/GMP/584202/2016 Work plan for the GMP/GDP Inspectors Working Group for 2017 Chairperson: David Cockburn Adopted: December 2016 1. Meetings scheduled for 2017 Face-to-face meetings
More informationEngagement with stakeholders
Engagement with stakeholders 2 nd International Awareness Session - The EU medicines regulatory system and the European Medicines Agency Presented by Juan Garcia Burgos and Marie-Helene Pinheiro on 8 March
More informationEU Update on Regulatory Developments
EU Update on Regulatory Developments Pascal Venneugues European Medicines Agency CASSS CMC Strategy Forum Europe Killarney, 22-24 May 2017 An agency of the European Union Overview International collaboration
More informationMarketing Authorisation Routes in the EU
Marketing Authorisation Routes in the EU The EU medicines regulatory system and the European Medicines Agency: an introduction for international regulators and non-governmental organisations 18 September
More informationPharmacovigilance: Information systems and services
Pharmacovigilance: Information systems and services Supporting business activities of the revised pharmacovigilance legislation through better information systems An agency of the European Union To deliver
More informationOptimising early access tools: Revision of the guidelines on Accelerated Assessment and Conditional Marketing Authorisation
Optimising early access tools: Revision of the guidelines on Accelerated Assessment and Conditional Marketing Authorisation High-level overview of comments received during the public consultation Presented
More informationMonthly statistics report: December 2017
19 January 2018 EMA/39932/2018 Information Management Division Medicinal products for human use (cumulative figures for the year to date) This document provides current information related to the volume
More informationMonthly statistics report: November 2016
7 December 2016 EMA/819205/2016 Information Management Division Medicinal products for human use (cumulative figures for the year to date) This document provides current information related to the volume
More informationPublication of Risk Management Plan (RMP) summaries:
Publication of Risk Management Plan (RMP) summaries: Analysis of the experience of the 1-year pilot phase PCWP meeting November 2015 An agency of the European Union Why produce a Summary of the Risk Management
More informationGuidance on preparing for Brexit in the centralised procedure
Guidance on preparing for Brexit in the centralised procedure SME info day: Regulatory toolbox for medicines and combined devices developers Presented by Leonor Enes on 26 October 2018 SME Office, Stakeholders
More informationEMA role in GMP Manufacturing and Quality Compliance
EMA role in GMP Manufacturing and Quality Compliance III all Russian GMP Conference Kazan 2018, Russia Presented by Roberto Conocchia Manufacturing and Quality Compliance European Medicines Agency An agency
More informationPublication of Risk Management Plan (RMP) summaries:
Publication of Risk Management Plan (RMP) summaries: Analysis of the experience of the 1-year pilot phase Presented by Juan Garcia Burgos and Caroline Voltz An agency of the European Union Outline Background
More informationThe role of patients at the EMA
The role of patients at the EMA Nathalie Bere Patient relations coordinator / European Medicines Agency An agency of the European Union What is the European Medicines Agency (EMA) The EMA is the EU regulatory
More informationEMA perspective on Quality Metrics
EMA perspective on Quality Metrics Indian Pharmaceutical Alliance Annual Congress, Mumbai India Presented by Brendan Cuddy on 24 February 2017 Head of Manufacturing and Quality Compliance, European Medicines
More informationScientific advice and its impact on marketing authorisation application reviews
Scientific advice and its impact on marketing authorisation application reviews SME info day: Tools to support innovative medicines development and early access Presented by Jan Regnström, MD, PhD Scientific
More informationPharmacovigilance. An agency of the European Union
Pharmacovigilance An agency of the European Union Pharmacovigilance is the science and activities relating to the detection, assessment, understanding and prevention of adverse reactions and other medicine-related
More informationThe European Medicines Agency: A well-established Agency of the EU protecting human and animal health for all EU citizens
14 July 2016 EMA/457243/2016 The European Medicines Agency: A well-established Agency of the EU protecting human and animal health for all EU citizens 1. Who we are The European Medicines Agency (EMA)
More informationEU scientific regulatory support mechanisms and initiatives for innovation in drug development: the EMA perspective
EU scientific regulatory support mechanisms and initiatives for innovation in drug development: the EMA perspective FAMHP Workshop, Brussels, 2 nd May 2016 Presented by Zahra Hanaizi Product Development
More informationEMA perspective on increasing focus on review of device components of medicinal products
EMA perspective on increasing focus on review of device components of medicinal products TOPRA Annual Human Medicines Symposium 2 4 October 2017 - Victoria Park Plaza Hotel, London Presented by Armin Ritzhaupt,
More informationStakeholders engagement
Stakeholders engagement The EU medicines regulatory system and the European Medicines Agency: an introduction for international regulators and non-governmental organisations 18-19 September 2017 Presented
More informationNew pharmacovigilance systems and services
New pharmacovigilance systems and services 17 September 2015, PCWP/HCPWP joint meeting Presented by Peter Arlett, Head of Pharmacovigilance department An agency of the European Union Background The new
More informationACG Public Forum. Join ACG, the FDA, and EMA for a discussion on biosimilars and IBD. Monday, 12:45 pm 2:15 pm
ACG Public Forum Join ACG, the FDA, and EMA for a discussion on biosimilars and IBD Monday, 12:45 pm 2:15 pm ACG 2017: FDA-EMA workshop on biosimilars Joachim Musaus EMA Product Lead Gastroenterology Human
More informationWork plan for the Biostatistics Working Party (BSWP) for 2018
14 December 2017 EMA/CHMP/333668/2017 Work plan for the Biostatistics Working Party (BSWP) for 2018 Chairperson: Anja Schiel Status of the work plan: December 2017 Adopted The activities outlined in the
More informationApplying for EU marketing authorisation. For medicinal products for human use. An agency of the European Union
Applying for EU marketing authorisation For medicinal products for human use An agency of the European Union Medicines can be authorised throughout the EU by means of a single application procedure. The
More informationExplanatory note on fees payable to the European Medicines Agency
30 March 2015 EMA/167155/2014 Executive Director Explanatory note on s payable to the European Medicines Agency The s, exemptions and definitions described in this Explanatory Note apply as of 1 April
More informationPharmacovigilance: Information systems and Services
Pharmacovigilance: Information systems and Services 3 rd Industry stakeholder platform operation of EU Pharmacovigilance legislation Presented by Peter Arlett Head of Pharmacovigilance Department An agency
More informationBetween Biosimilars and PRIME: EMA s report on regulatory trends and priorities for biopharmaceutical products
Between Biosimilars and PRIME: EMA s report on regulatory trends and priorities for biopharmaceutical products Dr Veronika Jekerle, Specialised Scientific Disciplines, EMA, London, UK CASSS-CMC Forum,
More informationSubmission of comments on 'Reflection paper on the use of extrapolation in the development of medicines for paediatrics' (EMA/199678/2016)
11 January 2018 Submission of comments on 'Reflection paper on the use of extrapolation in the development of medicines for paediatrics' (EMA/199678/2016) Comments from: Name of organisation or individual
More informationMandate and objectives for the EMA Working Party on Quality Review of Documents (QRD)
1 July 2014 EMA/403106/2014 Mandate and objectives for the EMA Working Party on Quality Review of Documents 1. General considerations The European Medicines Agency (EMA) created an ad hoc Working Group
More informationEarly interactions on innovation at EMA (ITF)
Early interactions on innovation at EMA (ITF) Session 2: Early interactions with regulators to support innovative medicines and technologies Presented by: Falk Ehmann, Science & Innovation Support (EMA)
More informationPRIority MEdicines (PRIME)
PRIority MEdicines (PRIME) Support to development of priority medicines for unmet medical needs. EuropaBIO information day, 15 October 2015 Jordi Llinares, Head of product development scientific support.
More informationMandate, objectives and rules of procedure for the CVMP Ad Hoc Expert Group on Veterinary Novel Therapies (ADVENT)
6 October 2016 EMA/CVMP/ADVENT/630299/2014 Rev.2 Committee for Medicinal Products for Veterinary Use (CVMP) Mandate, objectives and rules of procedure for the CVMP Ad Hoc Expert Group on Veterinary Novel
More informationWhat are the real-world evidence tools and how can they support decision making?
What are the real-world evidence tools and how can they support decision making? EMA-EuropaBio Info Day 22 nd November 2016 Dr Alison Cave, Principal Scientific Administrator, Pharmacovigilance and Epidemiology
More informationOrphan Medicines Figures
Orphan Medicines Figures 2000-207 Orphan Medicines - Product Development Scientific Support An agency of the European Union Applications for orphan medicinal product designation 2000 2006 20 206 207 Total
More informationInternational Collaborations in Pediatrics: FDA and EMA growing together March 2018
International Collaborations in Pediatrics: FDA and EMA growing together March 2018 Sandra L. Kweder, MD Deputy Director, Europe Office FDA Liaison to EMA U.S. Food and Drug Administration Disclaimer I
More informationReport from the Paediatric Committee on its first anniversary
European Medicines Agency London, 11 July 2008 Doc. Ref. EMEA/PDCO/347884/2008 Report from the Paediatric Committee on its first anniversary The European Medicines Agency s Paediatric Committee (PDCO)
More informationClinical Development and enabling Regulatory Steps: How to obtain ODD and Scientific Advice at EMA
Clinical Development and enabling Regulatory Steps: How to obtain ODD and Scientific Advice at EMA TELETHON Convention, Riva del Garda (TN) 15 March 2017 Michela Gabaldo Head Alliance Management & Regulatory
More informationRoles and responsibilities of members and alternates, rapporteur and peer reviewers, experts and observers of the Paediatric Committee (PDCO)
Last revision: 16 September 2010 EMA/537415/2008 Human Medicines Development and Evaluation Roles and responsibilities of members and alternates, rapporteur and peer reviewers, experts and observers of
More informationStrengthening the prospective discussions on post-licensing evidence generation
Strengthening the prospective discussions on post-licensing evidence generation Industry stakeholder platform on research and development support Presented by Jane Moseley on Senior Scientific Officer
More informationEMA/CAT support to ATMP developers
EMA/CAT support to ATMP developers CAT-ISCT Workshop: Challenge and opportunities for the successful development and approval of Advanced Therapy Medicinal Products. Presented by Patrick Celis on 25 September
More informationPharmacovigilance Post July 2012 The new frontier
Pharmacovigilance Post July 2012 The new frontier Colleen Walsh Head, Safety and Benefit Risk Management Quality, Biogen Idec 26th Annual EuroMeeting 25-27 March 2014 ACV, Vienna Austria Disclaimer The
More informationSummary of Product Characteristics Advisory Group (SmPC AG) activity report
14 March 2016 Scientific and Regulatory Management Department Summary of Product Characteristics Advisory Group (SmPC AG) 2010-2015 activity report Quality assurance of SmPCs 1. Introduction During the
More informationConsiderations on regulatory aspects
Considerations on regulatory aspects Regulatory framework for medicinal products in the context of therapeutic use of bacteriophages EMA Workshop on 8 June Presented by Zigmars Sebris on 8 June 2015 Regulatory
More informationWork plan for the CVMP Pharmacovigilance Working Party (PhVWP-V) 2018
30 January 2018 EMA/CVMP/PhVWP/384293/2017 Committee for Medicinal Products for Veterinary Use (CVMP) Work plan for the CVMP Pharmacovigilance Working Party (PhVWP-V) 2018 Chairpersons Chair: E. Dewaele
More informationInterested parties (organisations or individuals) that commented on the draft document as released for consultation.
9 November 2017 EMA/CHMP/CVMP/3Rs/83712/2017 Committee for Medicinal Products for Human Use (CHMP) Committee for Medicinal Products for Veterinary Use (CVMP) Overview of comments received on 'Guidance
More informationPriority Medicines (PRIME) scheme
Priority Medicines (PRIME) scheme DGRA Congress, Bonn, 15 June 2016 Presented by Christelle Bouygues Regulatory Affairs Officer An agency of the European Union Outline Why Prime? What is PRIME? PRIME Eligibility
More informationATMPs guideline on Safety and Efficacy follow-up and risk management
ATMPs guideline on Safety and Efficacy follow-up and risk management Presented by Caroline Voltz-Girolt EMA Product Lead - Oncology, Haematology and Diagnostics Office Scientific and Regulatory Management
More informationPRIME. 7 th STAMP meeting Brussels, 27 th June Presented by Sonia Ribeiro Head of Regulatory Affairs Office, Human Medicines Evaluation Division
PRIME 7 th STAMP meeting Brussels, 27 th June 2017 Presented by Sonia Ribeiro Head of Regulatory Affairs Office, Human Medicines Evaluation Division An agency of the European Union Overview of one-year
More informationExplanatory note on fees payable to the European Medicines Agency
09 December 2013 EMA/458574/2013 Executive Director Explanatory note on s payable to the European Medicines Agency The s, exemptions and definitions described in this Explanatory Note apply as of 1 January
More informationPilot of MAH signal detection in EudraVigilance
Pilot of MAH signal detection in EudraVigilance 13 th Industry Stakeholder Platform operation of EU pharmacovigilance Presented by Julie Durand Signal & Incident Management Service - Pharmacovigilance
More informationComments from: Name of organisation or individual. Merck Sharp & Dohme (MSD)
5 November 2015 EMA/733775/2015 Product Development Scientific Support Department Overview of comments on Total Kidney Volume (TKV) as a prognostic biomarker for use in clinical trials evaluating patients
More informationConditional marketing authorisation
Conditional marketing authorisation Report on ten years of experience at the EMA Presented by Zigmars Sebris on 27 June 2017 Regulatory Affairs Office, Human Medicines Evaluation Division An agency of
More informationSubstance & Product Management Services (P&SMS) update
Substance & Product Management Services (P&SMS) update P&SMS SG workshop & SPOR Task Force meetings 19-22 June 2018 An agency of the European Union Content 1. Summary 2. Iteration 1 data fields 3. PMS
More informationStakeholder Meeting, 17 June 2011, EMA, London. Fergus Sweeney, Head, Compliance and Inspections, European Medicines Agency
New Pharmacovigilance Legislation and Implementing Measures Minimum Requirements for Quality Systems (MAH, EMA, NCA), minimum requirements for Pharmacovigilance System Master File Stakeholder Meeting,
More informationEMA Working Groups on Committees' Operational Preparedness
EMA Working Groups on Committees' Operational Preparedness Mandate and objectives Industry Stakeholder Meeting on Brexit Presented by Monica Dias and Anthony Humphreys An agency of the European Union Background
More informationEU Portal and Database Update
EU Portal and Database Update TOPRA 4 October 2017 Presented by Noémie Manent on 4 October 2017 Committees and Inspections Department An agency of the European Union Table of content EMA Portal and Database
More informationSupervision of manufacturers: What is expected of National Competent Authorities?
Supervision of manufacturers: What is expected of National Competent Authorities? Fergus Sweeney, PhD, European Medicines Agency Head, Compliance and Inspections EU 28: Science, Medicines, Health Dubrovnik,
More informationOrphan Medicines Figures
Orphan Medicines Figures 000-05 Orphan Medicines - Product Development Scientific Support An agency of the European Union Status of Orphan Applications 000 005 006 00 0 0 03 04 05 Total Applications submitted
More informationThe EU Risk Management Plan - a tool to address the uncertainties at the time of approval, and manage the risks of medicines
The EU Risk Management Plan - a tool to address the uncertainties at the time of approval, and manage the risks of medicines Health care uncertainty assessment workshop Session 3: The challenges of health
More informationUpdate on EMA Brexit preparedness
Update on EMA Brexit preparedness SME Office Info Day on Supporting innovative medicines development and early access 17 November 2017 Presented by Anthony Humphreys An agency of the European Union EMA
More informationRegulatory point of view on clinical benefit assessment and parallel EMA/HTA advice
Regulatory point of view on clinical benefit assessment and parallel EMA/HTA advice Ateliers de Giens Meeting - French Society of Pharmacology and Therapeutics - Paris, March 23rd 2016 An agency of the
More informationEUnetHTA. European network for Health Technology Assessment. European network for Health Technology Assessment JA
EUnetHTA European network for Health Technology Assessment Outline The Making of EUnetHTA EUnetHTA and the HTA Network EUnetHTA Achievements and Tools General Information about HTA 2 The Making of EUnetHTA
More informationRegulatory Support to EU Research
Regulatory Support to EU Research OPEN INFO DAY Horizon 2020 'Health, demographic change and wellbeing Friday, 8 December 2017 Brussels Presented by Marisa Papaluca Senior Scientific Advisor, Scientific
More informationAnnex IV to guidance for the conduct of good clinical practice inspections sponsor and CRO
23 August 2017 EMA/431267/2016 Annex IV to guidance for the conduct of good clinical practice inspections sponsor Adopted by GCP Inspectors Working Group (GCP IWG) 29 November 2017 Keywords GCP inspection,
More informationGuidelines on good pharmacovigilance practices (GVP)
15 September 2014 EMA/475236/2014 Guidelines on good pharmacovigilance practices (GVP) Introductory cover note, last updated with revision 1 of module III on pharmacovigilance inspections and of module
More information1. Aim. 2. Who needs to complete an e-doi?
24 April 2015 EMA/627294/2014, Rev. 1 European Medicines Agency Procedural guidance on inclusion of declared interests in the European Medicines Agency s electronic declaration of interests form (for scientific
More informationThe Integration of Market Access and Advocacy: The Changing Landscape OCTOBER 2016
The Integration of Market Access and Advocacy: The Changing Landscape OCTOBER 2016 The Integration of Market Access and Advocacy: The Changing Landscape Introduction Healthcare market access and advocacy
More informationEudraVigilance: Preparing for Change
EudraVigilance: Preparing for Change EudraVigilance Auditable Requirement project 6 th Industry Stakeholder Platform Meeting, 18 th December 2015 Presented by Francois Domergue, Data Standardisation and
More informationSurvey report European Medicines Agency (EMA) consultation on the proposal of a collaboration framework with academia
20 October 2016 Stakeholders and Communication Division Survey report European Medicines Agency (EMA) consultation on the proposal of a collaboration framework with academia 30 Churchill Place Canary Wharf
More informationContent. Introduction: Approval of ATMPs. Support to ATMP developers. Role of EMA and National Competent Authorities
Content Introduction: Role of EMA and National Competent Authorities Approval of ATMPs What are ATMPs? Centralised procedure Support to ATMP developers 1 Introductory statements This talk is on marketing
More informationWe appreciate the opportunity to submit these comments for your consideration.
February 28, 2018 European Medicines Agency 30 Churchill Place Canary Wharf London E14 5EU United Kingdom via email to rp-stats-qa@ema.europa.eu Dear Sir or Madam: The International Society for Pharmaceutical
More informationMultiregional Regulatory Considerations in Pediatric Drug Development
Multiregional Regulatory Considerations in Pediatric Drug Development Lynne Yao, M.D. Director Division of Pediatric and Maternal Health Office of New Drugs Center for Drug Evaluation and Research U.S.
More informationto protect human health throughout the life-cycle of medicinal products;
ICMRA Communications Strategy: 2018-2020 Introduction The International Coalition of Medicines Regulatory Authorities (ICMRA) is a voluntary, highlevel, strategic coordinating, advocacy and leadership
More informationEudraVigilance auditable requirement project: ADRreports.eu portal update
EudraVigilance auditable requirement project: ADRreports.eu portal update Patients and Consumers Working Party 30 th November 2016 Francois Domergue, Business project manager An agency of the European
More informationHow are medicines evaluated at the EMA
How are medicines evaluated at the EMA Presented by: Nathalie Bere Patient interaction / Stakeholders and communication Division An agency of the European Union The European System Centralised Procedure
More informationEMA action plan related to the European Commission s recommendations on product information 1
14 November 2017 EMA/680018/2017 Stakeholders and Communication Division EMA action plan related to the European Commission s recommendations on product information 1 The European Medicines Agency (EMA)
More informationExplanatory note on general fees payable to the European Medicines Agency
Explanatory note on general fees payable to the European Medicines Agency The fees, fee exemptions and definitions described in this explanatory note apply as of 1 June 2017 and are based on Council Regulation
More informationBrexit Guidance for Stakeholders Human and veterinary medicines
Brexit Guidance for Stakeholders Human and veterinary medicines DATE: 03 JANUARY 2018 V.2 This guide does not purport to be an interpretation of law and/or regulations. The content provided is subject
More informationSenior Regulatory Affairs Executive AREAS OF EXPERTISE
Senior Regulatory Affairs Executive AREAS OF EXPERTISE More than fifteen years experience in vaccines, pharmaceuticals, biotechnology, and combination device products. Experience in regulatory strategy
More informationDuke Margolis Center for Health Policy
Duke Margolis Center for Health Policy International Harmonization of Expedited Programs: Challenges and Opportunities for Increasing Patient Access to Innovative Therapies Session I : Stakeholder experience
More informationDraft document circulated to Committees drafting group members 20 October Committees consultation November Adoption January 2015
28 January 2015 EMA/636600/2014 Human Medicines Research and Development Support Division Guidance on meetings with applicants on the responses to questions received from European Medicines Agency Scientific
More informationFurthermore, the level of information and the subsequent assessment will vary on a case by case basis.
17 March 2016 EMA/352178/2013 Committee for Medicinal Products for Human Use Committee for Medicinal Products for Veterinary Use Points to consider for the overall assessment of a supply shortage of a
More informationWork programme October 2017 EMA/583016/2016 Rev.1 1 Executive Director. 30 Churchill Place Canary Wharf London E14 5EU United Kingdom
9 October 2017 EMA/583016/2016 Rev.1 1 Executive Director 1 Project added to 2017 work programme, chapter 4: Support and governance activities 30 Churchill Place Canary Wharf London E14 5EU United Kingdom
More informationHow CAT Works: Regulatory Process, Patient Contribution and Outcomes
www.eurordis.org How CAT Works: Regulatory Process, Patient Contribution and Outcomes Michele Lipucci Di Paola AVLT/EURORDIS CAT/EMA Patient Representative michele.lipucci@eurordis.org EURORDIS MEMBERSHIP
More informationSignal Management in the EU and future extended access to EudraVigilance for industry
Signal Management in the EU and future extended access to EudraVigilance for industry 6 th Industry Stakeholder Platform Meeting, 18 th December 2015 Presented by Georgy Genov 7 December 2015 Head of Signal
More informationPharmacovigilance and product data
Future Legislation: pharmacovigilance EMA Veterinary Medicines Info Day 16-17 March 2017, London Presented by Jos Olaerts on 17 March 2017 European Medicines Agency - Veterinary Medicines Division An agency
More informationRegulatory update from Europe:
Regulatory update from Europe: Procedures to promote early access of medicinal products to the market Elmer Schabel MD Regulatory update from Europe - Overview Current tools for early access Conditional
More informationScientific and Regulatory Evaluation Procedure Support [S-REPS] Pilot Update / System Preview
Scientific and Regulatory Evaluation Procedure Support [S-REPS] Pilot Update / System Preview 3rd Industry Stakeholder Platform on R&D support, 18 May 2018 Presented by Sylvie Beausuroy [Project Manager],
More informationConsortium Internacional ACSS The ACSS Consortium
Consortium Internacional ACSS The ACSS Consortium VI Symposium Sindusfarma IPS/FIP - ANVISA 28-29 June 2017 Dr. Petra Doerr, Deputy Executive Director Swissmedic, Swiss Agency for Therapeutic Products
More informationWork plan for the joint CHMP/ CVMP Quality Working Party (QWP) for 2018
4 December 2017 EMA/CHMP/CVMP/QWP/504882/2017 Committee for Medicinal Products for Human Use (CHMP) Committee for Medicinal Products for Veterinary Use (CVMP) Work plan for the joint CHMP/ CVMP Quality
More informationWork programme Adopted by the Management Board on 18 December December 2014 EMA/773839/2014 Rev. 1 Management Board
18 December 2014 EMA/773839/2014 Rev. 1 Management Board Work programme 2015 Adopted by the Management Board on 18 December 2014 30 Churchill Place Canary Wharf London E14 5EU United Kingdom Telephone
More information